- Home
- PACK vs ALLO Comparison
PACK vs ALLO Comparison
Compare PACK & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PACK | ALLO |
|---|---|---|
| Founded | 1972 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.6M | 707.6M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PACK | ALLO |
|---|---|---|
| Price | $6.89 | $1.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $6.50 | ★ $8.35 |
| AVG Volume (30 Days) | 574.7K | ★ 10.7M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $395,000,000.00 | N/A |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.35 | $142,416.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $3.22 | $0.99 |
| 52 Week High | $7.81 | $4.46 |
Technical Indicators
Market Signals| Indicator | PACK | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 40.06 |
| Support Level | $6.59 | $1.85 |
| Resistance Level | $7.16 | $1.92 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 46.85 | 1.43 |
Price Performance
Historical ComparisonAbout PACK Ranpak Holdings Corp
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).